At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,229 enrolled
Drug / intervention
Sulopenem etzadroxil/probenecid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women
In Brief
A Phase 3 clinical trial evaluating Sulopenem etzadroxil/probenecid and Amoxicillin/clavulanate for Urinary Tract Infections and Cystitis. Completed, enrolled 2,229 participants across 167 sites.
Detailed Summary
Study 310 is a clinical study which compares the effectiveness of oral sulopenem versus oral amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infections, Cystitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartOct 2022
Primary CompletionNov 2023
Study CompletionNov 2023
TodayJul 2026
First PostedOct 18, 2022
Enrollment StartOct 18, 2022
Primary CompletionNov 3, 2023
Study CompletionNov 21, 2023
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.7 years ago
Interventions
Sulopenem etzadroxil/probeneciddrug
Oral sulopenem twice daily for 5 days
Amoxicillin/clavulanatedrug
Oral Augmentin twice daily for 5 days